Nodal marginal zone lymphoma in the pediatric and young adult population is relatively rare, with specific clinicopathological features that led to the delineation of pediatric nodal marginal zone ...

Dura-based marginal zone lymphomas represent an uncommon group of low-grade B-cell neoplasms, and literature regarding the clinical, histological and genetic profile of these tumors in the context of ...

A treatment combination that includes Velcade and Rituxan helps improve responses and the safety profile in marginal zone lymphoma, according to a phase 2 trial. Velcade (bortezomib), Rituxan ...

Breyanzi achieved a 95.5% response rate in relapsed or refractory marginal zone lymphoma, with 62.1% complete responses and 88.6% ongoing at 24 months. The therapy maintained a consistent safety ...

Extranodal Marginal Zone Lymphoma: No Longer Just a Sidekick. If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply ...

Please provide your email address to receive an email when new articles are posted on . The results were presented at Society of Hematologic Oncology’s Annual Meeting. “We currently are really missing ...

PLYMOUTH MEETING, PA [September 12, 2022] — The National Comprehensive Cancer Network ® (NCCN ®) has published new NCCN Guidelines for Patients ®: Marginal Zone Lymphoma. A cancer of the lymphatic ...

Bristol Myers Squibb has taken CAR-T therapy of blood cancers into new territory, after getting FDA approval for Breyanzi as a treatment for relapsed or refractory marginal zone lymphoma (MZL).

An evidence-based, expert consensus resource, available for free at NCCN.org/patientguidelines, helps people understand a rare and complex cancer type PLYMOUTH ...